



Press release
July 13, 2017
Gothenburg

Recruitment completed for PrimeECC study

PrimeECC® is a CE-marked and patent-protected product, developed to prime the heart-lung machine before open heart surgery. A previous “proof of concept” study performed using PrimeECC® has shown interesting clinical results. Recruitment is now complete for a study including a total of 80 patients that aims to increase the clinical documentation for PrimeECC®. Analysis of the results will now begin and it is estimated that the first publication from the study will be towards the end of 2017.

Several hundred thousand heart operations are performed in the world each year using a heart-lung machine and the ‘proof of concept’ study performed using PrimeECC® indicates that the patient has an improved fluid balance after the operation if the heart-lung machine is primed with PrimeECC® rather than the simpler solutions that are often used. During the past year the company has carried out a randomized, blind clinical study on 80 patients at Sahlgrenska University Hospital in Gothenburg in order to increase the documentation. All patients have now been included and it is estimated that the first results will be published towards the end of 2017.

Professor Anders Jeppsson, who is in charge of the study, is pleased that the recruitment of patients has gone according to plan and looks forward with interest to analyzing the results.

XVIVO Perfusion is waiting for analysis of the results from the study at Sahlgrenska University Hospital and does not plan any extensive launch of the product before the results from the study have been published. XVIVO Perfusion has applied for a patent for PrimeECC® in important markets and has so far been granted a patent in the USA, EU, China and Japan.

PrimeECC® is a fluid developed in collaboration with Professor Stig Steen in Lund to prime heart-lung machines before use. These machines are used to maintain blood circulation and take over oxygenation of the blood during heart operations. The fluid is used to compensate for the volume of blood that is outside the patient and in the heart-lung machine during the operation. Today simple saline solutions are used which are not optimized for this purpose. The aim of PrimeECC® is to minimize adverse effects that may arise during and after use of a heart-lung machine.

“We are delighted that recruitment for the clinical study on PrimeECC® is now complete, as the product has interesting clinical and commercial potential. We look forward to the results from the study which it is estimated will come later this year,” says XVIVO Perfusion’s CEO Magnus Nilsson.

July 13, 2017
Gothenburg
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, tel: +1 720 616 2101, email: christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, tel +46 31 788 2150, email: magnus.nilsson@xvivoperfusion.com

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The Xvivo share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CET on July 13, 2017.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.